(Chlorthalidone + losartan) is under clinical development by Laboratorios Silanes and currently in Phase III for Idiopathic (Essential) Hypertension. According to GlobalData, Phase III drugs for Idiopathic (Essential) Hypertension does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the (Chlorthalidone + losartan) LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Chlorthalidone + losartan) overview

A fixed-dose combination of chlorthalidone and losartan is under development for the treatment of essential arterial hypertension. It is administered through oral route. Chlorthalidone act by targeting sodium chloride cotransporter and losartan acts by targeting angiotensin II receptor (type AT1).

Laboratorios Silanes overview

Laboratorios Silanes is a manufacturer and supplier of pharmaceutical products. The company’s portfolio includes a broad range of analgesics, products for neurological disorders, metabolic diseases, tuberculosis, pain, asthma, and oral anti-diabetics. It also offers diagnostics and nutraceutical solutions. Through its subsidiary, Instituto Bioclon SA de CV, the company offers antivenom products. Laboratorios Silanes conducts research to develop generics for captopril, lysine clonixinate, enalapril, and carbamazepine, among others; and develop antibody based products and therapeutic peptides for the treatment of ocular, neurodegenerative, inflammatory, autoimmune, and infectious diseases and diabetes. The company licensed the development of glimepiride and metformin to its commercial partner, Sanofi. Laboratorios Silanes is headquartered in Mexico City, Mexico.

For a complete picture of (Chlorthalidone + losartan)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.